Development and validation of a prognostic model for overall survival in chemotherapy-naive men with metastatic castration-resistant prostate cancer (mCRPC) from the phase III PREVAIL clinical trial.

被引：0
|
作者：
Armstrong, Andrew J.
Lin, Ping
Higano, Celestia S.
Sternberg, Cora N.
Sonpavde, Guru
Tombal, Bertrand F.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 06期
关键词：
D O I：
10.1200/JCO.2017.35.6_suppl.138
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
138
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Budget Impact of Enzalutamide for Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
    Bui, Cat N.
    O'Day, Ken
    Flanders, Scott
    Oestreicher, Nina
    Francis, Peter
    Posta, Linda
    Popelar, Breanna
    Tang, Hong
    Balk, Mark
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2016, 22 (02): : 163 - U171
  • [22] Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
    George, Daniel J.
    Ramaswamy, Krishnan
    Huang, Ahong
    Russell, David
    Mardekian, Jack
    Schultz, Neil M.
    Janjan, Nora
    Freedland, Stephen J.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2022, 25 (03) : 524 - 530
  • [23] A correlative biomarker study and integrative prognostic model in chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide
    Fernandez-Perez, Maria P.
    Perez-Navarro, Enrique
    Alonso-Gordoa, Teresa
    Conteduca, Vicenza
    Font, Albert
    Vazquez-Estevez, Sergio
    Gonzalez-del-Alba, Aranzazu
    Wetterskog, Daniel
    Antonarakis, Emmanuel S.
    Mellado, Begona
    Fernandez-Calvo, Ovidio
    Mendez-Vidal, Maria J.
    Climent, Miguel A.
    Duran, Ignacio
    Gallardo, Enrique
    Rodriguez Sanchez, Angel
    Santander, Carmen
    Saez, Maria, I
    Puente, Javier
    Tudela, Julian
    Martinez, Alberto
    Lopez-Andreo, Maria J.
    Padilla, Jose
    Lozano, Rebeca
    Hervas, David
    Luo, Jun
    de Giorgi, Ugo
    Castellano, Daniel
    Attard, Gerhardt
    Grande, Enrique
    Gonzalez-Billalabeitia, Enrique
    PROSTATE, 2023, 83 (04): : 376 - 384
  • [24] Real-world treatment with abiraterone acetate in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)
    Boegemann, Martin
    Hatzinger, Martin
    Hercher, Dirko
    Matus, Geoffrey
    Everaert, Els Grieta
    Dopchie, Catherine
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [25] The effect of therapeutic anticoagulation on overall survival (OS) in men receiving docetaxel chemotherapy for metastatic castration-resistant prostate cancer (mCRPC)
    Pratz, Caroline F.
    Brodsky, Robert A.
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [26] Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial
    Zurita, A. J.
    George, D. J.
    Shore, N. D.
    Liu, G.
    Wilding, G.
    Hutson, T. E.
    Kozloff, M.
    Mathew, P.
    Harmon, C. S.
    Wang, S. L.
    Chen, I.
    Maneval, E. Chow
    Logothetis, C. J.
    ANNALS OF ONCOLOGY, 2012, 23 (03) : 688 - 694
  • [27] Enzalutamide in Men With Chemotherapy- Naive Metastatic Prostate Cancer (mCRPC): Results of Phase III PREVAIL Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2014, 12 (04) : 3 - 4
  • [28] Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL
    Graff, J. N.
    Baciarello, G.
    Armstrong, A. J.
    Higano, C. S.
    Iversen, P.
    Flaig, T. W.
    Forer, D.
    Parli, T.
    Phung, D.
    Tombal, B.
    Beer, T. M.
    Sternberg, C. N.
    ANNALS OF ONCOLOGY, 2016, 27 (02) : 286 - 294
  • [29] A phase III, randomized study of the investigational agent TAK-700 plus prednisone for patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC).
    Saad, F.
    Akaza, H.
    Eisenberger, M. A.
    Nelson, J.
    Scher, H. I.
    Suzuki, K.
    Wirth, M.
    Webb, I. J.
    Wang, J.
    MacLean, D.
    De Wit, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [30] Cabazitaxel vs docetaxel in chemotherapy-naive (CN) patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm phase III study (FIRSTANA).
    Sartor, A. Oliver
    Oudard, Stephane
    Sengelov, Lisa
    Daugaard, Gedske
    Saad, Fred
    Hansen, Steinbjoern
    Hjelm-Eriksson, Marie
    Jassem, Jacek
    Thiery-Vuillemin, Antoine
    Caffo, Orazio
    Castellano, Daniel E.
    Mainwaring, Paul N.
    Bernard, John P.
    Shen, Liji
    Chadjaa, Mustapha
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345